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ABSTRACT
The ability to efficiently generate targeted point
mutations in the chromosome without the need
for antibiotics, or other means of selection, is a
powerful strategy for genome engineering.
Although oligonucleotide-mediated recombineering
(ssDNA recombineering) has been utilized in
Escherichia coli for over a decade, the successful
adaptation of ssDNA recombineering to Gram-
positive bacteria has not been reported. Here we
describe the development and application of
ssDNA recombineering in lactic acid bacteria.
Mutations were incorporated in the chromosome
of Lactobacillus reuteri and Lactococcus lactis
without selection at frequencies ranging between
0.4% and 19%. Whole genome sequence analysis
showed that ssDNA recombineering is specific and
not hypermutagenic. To highlight the utility of
ssDNA recombineering we reduced the intrinsic
vancomymycin resistance of L. reuteri >100-fold.
By creating a single amino acid change in the
D-Ala-D-Ala ligase enzyme we reduced the
minimum inhibitory concentration for vancomycin
from >256 to 1.5mg/ml, well below the clinically
relevant minimum inhibitory concentration.
Recombineering thus allows high efficiency muta-
genesis in lactobacilli and lactococci, and may be
used to further enhance beneficial properties and
safety of strains used in medicine and industry.
We expect that this work will serve as a blueprint
for the adaptation of ssDNA recombineering to
other Gram-positive bacteria.
INTRODUCTION
Lactococci and lactobacilli are lactic acid bacteria (LAB)
that are commonly used in industry for the fermentation
of food and beverage products. Also, numerous strains are
of interest to both the industrial and medical communities
as they elicit health-promoting properties to the host [for a
review see (1,2)]. As many LAB are generally recognized
as safe, lactobacilli and lactococci have been genetically
engineered to serve as protein delivery vehicles (3–5), or
have been modiﬁed for optimized production of metabolic
products (6–10). In the United States and Western Europe
the use of LAB strains in industry and medicine represents
a multi-billion dollar market that is predicted to expand in
the coming years.
Recombineering was developed in Escherichia coli and
refers to ‘Engineering recombinant DNA molecules by
in vivo homologous recombination’ (11). Initial applica-
tions of this technology relied on the expression of three
lambda ( ) phage-derived proteins: Beta, Gam and Exo,
collectively named the  -Red system (12,13). Beta is a
single-stranded DNA (ssDNA)-binding protein, Gam
suppresses host nucleases, and Exo is a 50–30 exonuclease.
Double-stranded DNA with short ﬂanking sequences
homologous to the target site is introduced into cells ex-
pressing the  -Red proteins and single-stranded overhangs
are generated by Exo. These overhangs are subsequently
bound by Bet, followed by a homologous recombination
event at the target site.
More recent applications of recombineering involve
single-stranded oligonucleotides as a substrate rather
than double-stranded DNA. In this case only expression
of Bet, or the functional homolog RecT of the Rac
prophage, is required to incorporate the ssDNA into the
genome (11). In E. coli, ssDNA recombineering is most
efﬁcient with oligonucleotides that are 40–70bp (11,14),
and there is a lagging-strand bias in both E. coli and
Mycobacterium (11,15). In E. coli the efﬁciency of
recombineering is impacted by the methyl-directed
mismatch repair system (MMR) (16,17). With proper
oligonucleotide design the MMR may be avoided in
E. coli by using oligonucleotides yielding C C
mismatches, multiple adjacent mismatches, multiple
mismatches at consecutive wobble base positions
(11,14,18,19), or the use of chemically modiﬁed bases
(17) yielding a recombinant genotype in 20–50% of the
population (16,17). These levels are high enough to
identify mutations without the need for antibiotic
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recombineering levels only allowed identiﬁcation of
mutants within the pool of cells that were able to take
up plasmid DNA (20). In ssDNA recombineering it has
been proposed that the oligonucleotide is incorporated via
an annealing and replication-dependent mechanism
(11,21) rather than by homologous recombination. The
ssDNA recombineering has been demonstrated in Gram-
negative bacteria (11,22–24), and in Mycobacterium (20).
In this study we describe the development of targeted
ssDNA recombineering in Lactobacillus reuteri ATCC
PTA 6475, a human isolate which is a candidate probiotic
with anti-inﬂammatory properties (25,26) without the
need for antibiotic selection (Figure 1). Also, we
extended this technology to Lactococcus lactis which is
widely used in the dairy industry for fermentation
processes and has been applied as a biotherapeutic
delivery vehicle (3,27). RecT-mediated recombineering
is not hypermutagenic, and may serve as a powerful
and novel tool for strain improvement through directed
evolution by genetic engineering in LAB. The use of
recombineering in the development of LAB as
biotherapeutics is discussed.
MATERIALS AND METHODS
Bacterial strains, plasmids and media
Bacterial strains and plasmids used in this study are listed
in Supplementary Table S1. Lactobacilli and their deriva-
tives were cultured under anaerobic conditions at 37 C
in deMan Rogosa Sharpe (MRS) medium (Difco, BD
BioSciences). Lactococcus and its derivatives were
cultured static at 30 C in M17-broth (Difco, BD
BioSciences) that was supplemented with glucose to a
ﬁnal concentration of 0.5% (w/v). Electrocompetent cells
of lactobacilli and Lactococcus were prepared as described
before (28–30). If required, antibiotics were added as
follows: 5mg/ml erythromycin or chloramphenicol for
lactobacilli and Lactococcus, 25 and 50mg/ml rifampicin
for lactobacilli and lactococci, respectively.
Reagents and enzymes
Restriction enzymes and T4 DNA ligases were purchased
from New England Biolabs (NEB). PCR amplicons for
cloning purposes were generated by KOD DNA hot
start polymerase (Novagen), and PCR reactions for
screening purposes were performed with Taq DNA poly-
merase (Denville Scientiﬁc). Pellet Paint Precipitant
(Novagen) was used to precipitate DNA prior to restric-
tion digestion, ligation and transformation. All oligo-
nucleotides used in this study were purchased from
Integrated DNA Technologies.
Construction of RecT expression vectors: pJP005 and
pJP042
Oligonucleotides for cloning are listed in Supplementary
Table S2. The RecT expression vectors (pJP005 and
pJP042) were constructed as follows: pNZ8048 was
digested with NcoI and KpnI, followed by Pellet Paint
precipitation (Novagen). Genomic DNA of L. reuteri
ATCC PTA 6475 (Wizard genomic DNA puriﬁcation
kit, Promega) was used as template for PCR ampliﬁcation
of the recT1 gene with oligonucleotide pair oJP022–
oJP023, and the amplicon was digested and precipitated
as described for pNZ8048. Puriﬁed DNA was quantiﬁed
using Nanodrop-1000 (Thermo Scientiﬁc), and ligations
were performed using a 1:1 (vector:insert) molar ratio
using conditions speciﬁed by the manufacturer (NEB).
The ligation mixture was transformed in L. lactis
NZ9000, and Cm-resistant colonies were subjected to
colony PCR with oligonucleotides that ﬂank the
multiple cloning site (oJP024–oJP025). Insertion was
veriﬁed by restriction digest analysis and the integrity of
the sequence was conﬁrmed by sequence analysis. The re-
sultant construct was named pJP005.
pSIP411 (a kind gift from Lars Axelsson, Noﬁma,
Norway) is known to yield inducible and titratable gene
expression in L. reuteri ATCC PTA 6475 (Lars Axelsson,
personal communication) and was therefore used for this
work. The backbone of pSIP411 was ampliﬁed with oligo-
nucleotide pair oJP367–oJP368, followed by Pellet Paint
precipitation, and digestion with NcoI and XbaI. Using
oligonucleotide pair oJP369–oJP370 recT1 was ampliﬁed
as described above, and the amplicon was puriﬁed
followed by digestion with NcoI and XbaI. Ligation was
performed as described for the construction of pJP005,
and the ligation mix was transformed in L. lactis
MG1363. Em-resistant colonies were screened by colony
PCR for insertion of recT using oligonucleotide pair
oJP415–oJP416. Integrity of the resultant clone, hereafter
referred to as pJP042, was done in an identical manner as
described for pJP005.
Preparation of cells for recombineering
All recombineering experiments with lactobacilli harbor-
ing pJP042 were performed with the following conditions:
induction at OD600>0.55 and <0.65 for 20min with
10ng/ml induction peptide (MAGNSSNFIHKIKQI
FTHR; Peptide2.0 Inc), followed by 5min incubation on
ice and preparation of competent cells as described above.
All electroporations described were performed with a
BioRad Genepulser and 2-mm electroporation cuvettes
(BioRad).
Lactococcus lactis NZ9000 harboring pJP005 was
induced for 30min with 0.1% (v/v) ﬁlter-sterilized nisin
at OD600>0.2 and <0.3, followed by preparation of com-
petent cells. Nisin was derived from an overnight culture
of L. lactis NZ9700, and aliquots were stored at  20 C for
up to 6months.
Optimization of recombineering in L. reuteri
All oligonucleotides for recombineering are listed in
Supplementary Table S2. Oligonucleotides for recom-
bineering purposes were ordered at 100nmol scale,
desalted, and without any puriﬁcations. All recom-
bineering oligonucleotides are complementary to the
leading strand, and the non-complementary bases for all
recombineering oligonucleotides are located centrally.
With exception of the experiment to assess the effect of
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efﬁciency, we used 100mg of oligonucleotide. Electro-
competent cells harboring pJP042 were prepared as
described above, and for all experiments a volume of
5ml (oligonucleotide or water) was electroporated. One
microlitre of MRS was added, and bacteria were re-
covered for 2.5h followed by serial dilution plating on
MRS agar plates and MRS agar plates containing
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Figure 1. Overview of recombineering in L. reuteri. (i) Electrocompetent cells in which RecT is expressed are transformed with a recombineering
oligonucleotide. Transformation efﬁciencies of    10
5cfu/mg DNA are required for high recombineering efﬁciencies. Wavy black lines with a red dot
represent recombineering oligonucleotides with multiple non-complementary bases; the green circle represents a bacterial cell; pJP042 is the
sakacin-based expression vector that contains recT; the black double helix represents chromosomal DNA; expressed RecT proteins are denoted
in the cell. (ii) An oligonucleotide identical to the lagging strand contains multiple non-complementary bases that avoid the mismatch repair system
resulting in increased recombineering efﬁciency. (iii) Viable cells are recovered on antibiotic-free plates and recombinants are detected by a mismatch
ampliﬁcation mutation assay-PCR (MAMA-PCR). Two oligonucleotides (blue) will yield a 1-kb fragment, whereas a third oligonucleotide (red) will
only be extended by the polymerase when the mutations are incorporated in the chromosome yielding a second amplicon of 500bp. As the
recombineering oligonucleotide only targets one strand during DNA replication the colonies will be of mixed genotype. The red dot on the
chromosome indicates that the mutations are incorporated. (iv) Single colony puriﬁcation is performed to separate the wild-type genotype from
the mutant genotype. (v) MAMA-PCR is repeated as described in section iii to identify a pure genotype mutant. A 1:1 ratio of wild-type and mutant
genotypes is suggestive that during replication a single chromosome is being replicated per cell. (vi) The recombineering plasmid pJP042 can now be
cured from the mutant strain by passaging bacteria without antibiotic selection to yield a plasmid-free derivative (vii).
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To assess the efﬁciency of recombineering in relation to
a single or multiple mismatches we targeted the rpoB gene.
Based on work in E. coli (31) we predicted the amino acid
change H488R would yield a rifampicin-resistant pheno-
type. Oligonucleotides had a single mismatch (oJP133), or
multiple mismatches (oJP311 and oJP577). No multiple
mismatches could be designed which, when incorporated
into a new DNA strand, would be silent mutations. As it is
unknown whether an amino acid change adjacent to H488
affects the rifampicin-resistant phenotype, we identiﬁed
experimentally which amino acid change would still yield
a rifampicin-resistant phenotype, yielding oJP311 and
oJP577.
Other optimization studies, including the effect of oligo-
nucleotide concentration or multiple mutations in the
wobble base in relation to the recombineering efﬁciency,
were performed in an identical manner as described above.
Non-selected recombineering in L. reuteri
Competent cells of L. reuteri harboring pJP042 were trans-
formed with 100mg oligonucleotide oJP577 and after
recovery serial dilutions were plated on MRS plates.
One hundred colonies were replica plated on MRS agar
plates and MRS agar plates containing 25mg/ml rifampi-
cin. Rifampicin-resistant colonies were subjected to PCR
(using oligonucleotides oJP097–oJP098) followed by
sequence analysis to conﬁrm incorporation of the
recombineering oligonucleotide.
For genes other than rpoB, a selection of genes was
chosen that targeted different regions of the chromosome
of L. reuteri. For each gene a 90-mer oligonucleotide was
designed with multiple consecutive mismatches. With ex-
ception of oJP475 and oJP810, recombineering oligo-
nucleotides were designed such that an in-frame stop
codon and a restriction endonuclease recognition site
(either EcoRI, BamHI or HindIII) were created upon in-
corporation. For all genes 100mg recombineering oligo-
nucleotide was transformed and after recovery serial
dilutions were spread on MRS plates without antibiotic
selection. From the pool of transformants approximately
300 colonies were subjected to screening. We applied two
screening strategies. The ﬁrst strategy involves identiﬁca-
tion of mutations by restriction digest when the mutation
being incorporated generated a new restriction site. PCR
ampliﬁcation of a 1-kb fragment in which the target site is
located centrally was performed. Amplicons were subse-
quently subjected to restriction digest analysis with the
appropriate enzyme. A partial or completely digested
amplicon was indicative of incorporation of the
recombineering oligonucleotide. The rationale for the
partial digest is that one strand is targeted by oligonucleo-
tide recombineering, i.e. the PCR product can be derived
from mixed genotypes yielding a mix of amplicons.
Alternatively, a fully digested amplicon can be expected
if the mixed genotypes separated during recovery. The
second method is a mismatch ampliﬁcation mutation
analysis–PCR (MAMA–PCR) (32,33), and relies on the
use of an oligonucleotide of which the 30-end is
complementary to the recombinant sequence. Upon iden-
tiﬁcation of a recombinant genotype by either method,
cells were streaked on plate to separate the genotypes
followed by screening to identify a pure genotype. The
oligonucleotide sequences related to the targets listed in
Figure 3b are available upon request.
Recombineering in other LAB
We isolated natural rifampicin-resistant mutants for
Lactobacillus plantarum BAA-793, Lactobacillus gasseri
ATCC 33323, and L. lactis NZ9000, and determined the
sequence of rpoB by sequence analysis. For lactobacilli,
10
9 cells were plated on MRS containing 25mg/ml rifam-
picin whereas for Lactococcus 10
9 cells were plated on
GM17 harboring 50mg/ml rifampicin. Five rifampicin-
resistant colonies of each strain were subjected to PCR
using oligonucleotide pair oJP451–oJP458, oJP497–
oJP505 and oJP528–oJP536 for L. plantarum, L. gasseri
and L. lactis, respectively, and the sequence of the
amplicons was determined and analyzed. Mutations that
were identiﬁed in the rpoB genes were a G-T transversion
at position 1438 (H480Y) for L. plantarum, a C–T transi-
tion at position 1468 (H490Y) for L. gasseri, and a C-A
transversion at position 1456 (H486N) for L. lactis. Next
we designed recombineering oligonucleotides targeting the
rpoB gene for L. plantarum (oJP492), L. gasseri (oJP579)
and L. lactis (oJP547 and oJP563). For L. gasseri we
designed an oligonucleotide that, when incorporated,
yields the amino acid changes T489S and H490R, and
we determined experimentally that these changes yield a
rifampicin-resistant phenotype. Competent cells for
recombineering purposes were prepared as described
above, followed by transformation of 100mg of the cor-
responding oligonucleotides. The number of rifampicin-
resistant colonies were determined and expressed per 10
9
viable cells.
For construction of a double mutant by recombineering
in L. lactis NZ9000, competent cells expressing RecT were
transformed with 50mg oJP563 (to yield a rifampicin-
resistant phenotype) and 50mg oJP584 which targets
malG, and transformants were recovered on GM17 agar
plates harboring 50mg/ml rifampicin. A total of approxi-
mately 300 rifampicin-resistant colonies were screened by
MAMA-PCR using oligonucleotides oJP575, oJP576 and
oJP598. Two percent of the screened colonies yielded two
amplicons, indicative for co-incorporation of oJP584. A
streak plate was made to separate the genotypes, and sub-
sequently 10 colonies were screened with the above oligo-
nucleotides to identify a pure genotype yielding strain
RPRB4004.
Mutating the active site of Ddl
Active site residues of the Ddl protein of E. coli had pre-
viously been identiﬁed and in vitro analysis with recom-
binant protein showed that a single amino acid change
(Y216F) could convert a dipeptide ligase to a depsipeptide
ligase (34). To identify the corresponding active site of Ddl
from L. reuteri ATCC PTA 6475 we ﬁrst obtained the pre-
dicted 3D structure using the SWISS-MODEL server (35).
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tural overlay of Ddl proteins derived from L. reuteri and
E. coli (37) to determine the predicted active site residue of
Ddl L. reuteri that corresponds to the Y216 of E. coli, and
this was predicted to be F258 for Ddl-L. reuteri. E. coli
crystal structures (PDB ID: 1IOV for wild-type, and
1IOW for Ddl-Y126F) were obtained from the RCSB
protein data bank.
An 80-mer oligonucleotide was designed (oJP810)
which, upon incorporation, yields seven base changes
which resulted in a single amino acid change (F258Y).
Electrocompetent cells expressing RecT1 were trans-
formed with 100mg oJP810. We anticipated a slower
growth phenotype for Ddl (F258Y) compared to the
wild-type strain. Overgrowth by wild-type cells in a
mixed population makes it difﬁcult to identify of a
mutant genotype by colony screening. We therefore re-
covered the cells for 4h instead of 2.5h to allow separ-
ation of the genotypes, and plated the cells on MRS agar
plates. After three days incubation, seven small colonies
were subjected to PCR with oligo pair oJP697–oJP698 to
yield a 500-bp product (Supplementary Figure S1),
followed by ApoI restriction digest analysis according to
the manufacturer speciﬁed conditions. As incorporation
of oJP810 alters a single ApoI recognition site in the
amplicon it is expected that an undigested PCR product
is indicative for a mutant genotype (Supplementary Figure
S1). Digested amplicons which yielded fragments corres-
ponding to 300 and 200bp are indicative for a wild-type
genotype. The resultant mutant strain was named
RPRB3003.
Vancomycin susceptibility testing
The susceptibility to vancomycin was assessed with Etest
strips (BioMe ´ rieux), and the minimum inhibitory concen-
tration (MIC) was expressed as micrograms per millilitre.
The range of vancomycin concentrations tested on the
strip was 0.016–256mg/ml. The assay was performed as
previously described (38).
Whole genome sequence analysis
We found that introduction of pSIP411 or its derivatives
in L. reuteri ATCC PTA 6475 introduces a null-mutation
in locus HMPREF0536_1706 in a sub-population of the
transformants (unpublished results, Laura Ortiz, JPVP
and RB). Prior to whole genome sequence analysis
strains were selected in which no mutation was present
in this locus. After identiﬁcation of the mutant
genotype, strains were cured from pJP042 by growing
the strains for one passage without antibiotic selection
followed by plating on non-selective MRS agar plates.
By patch plating we identiﬁed erythromycin-sensitive
colonies that are considered cured from pJP042. All
strains with exception of RPRB1696 were subjected by
Illumina genome sequencing by the Research
Technology Support Facility (RTSF) at Michigan State
University. Genomic DNA from L. reuteri and L. lactis
was isolated with the Wizard Genomic DNA kit
(Promega). For whole genome sequencing, genomic
DNA samples were further processed with the Illumina
Genomic Sample Prep kit according to the manufacturer’s
recommendations. Paired-end 75 base runs were per-
formed on the Illumina GAIIx sequencer(39). Strain
RPRB1696 was subjected to whole genome sequencing
using a Roche 454 GS Junior sequencer. Samples were
prepared according to the manufacturer’s recommenda-
tions. Reads were mapped to the closed L. reuteri F275
genome sequence yielding for the Illumina data on average
139±14-fold depth and 99.986±0.01% genome
coverage. The 454 sequencing resulted in a 36-fold depth
and 99.446% genome coverage. Fold depth and coverage
percentages were determined using the utility genome
CoverageBed within the BEDtools suite(40).
SNP analysis was performed with the software
packages ‘From Reads to Results (R2R)’(41), MAQ
(Sourceforge) and BWA(42) using standard settings.
Identiﬁed SNPs in each of the recombineered strains
were conﬁrmed by PCR ampliﬁcation of the mutated
region followed by sequence analysis. The presence of
larger INDELs and inversions was assessed by MAQ,
BWA and Pindel(43).
RESULTS
Establishing recombineering in L. reuteri ATCC
PTA 6475
Although there are several genetic tools available for LAB
(44–47) there is no system to generate targeted point mu-
tations in the chromosomes of members of the phylum
Firmicutes without the need for antibiotic selection.
Therefore we wanted to establish ssDNA recombineering
in L. reuteri that may serve as a model for other
lactobacilli and lactococci. Using E. coli recT as a query
we searched the draft genome sequence of L. reuteri
ATCC PTA 6475 and identiﬁed two recT homologs,
recT1 (locus tag HMPREF0536_0455) and recT2 (locus
tag HMPREF0536_0582).
To assess the ability of the L. reuteri RecT proteins to
support recombineering we placed recT1 under the control
of an inducible promoter using the sakacin-based expres-
sion vector pSIP411(48) to yield plasmid pJP042. A simple
method to quantitatively assess the efﬁcacy of recom-
bineering is to mutate a site in the RNA polymerase
gene (rpoB) that results in an amino acid change yielding
a rifampicin-resistant phenotype. We designed an 80-mer
oligonucleotide (oJP133) targeting the lagging strand of
DNA synthesis which has a single centrally located
non-complementary base that results in a C A mismatch
(Figure 2a). Incorporation of oJP133 generates the amino
acid change H488R in RpoB that confers rifampicin re-
sistance in L. reuteri. After optimization of RecT1 expres-
sion conditions (data not shown), transformation of 1mg
oJP133 yielded approximately a 10-fold increase in
rifampicin-resistant colonies compared to background
levels (Figure 2b). Expression of RecT2 yielded similar
recombineering efﬁciencies (data not shown), and we
used RecT1 for all future recombineering experiments in
L. reuteri.
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recombineering
In E. coli recombineering levels are saturated when using
 115ng of a 70 base oligonucleotide(14,49). To assess
whether recombineering in L. reuteri is saturated with
1mg, we transformed oJP133 over a two-log range with
a maximum of 100mg oligonucleotide (Figure 2b). There is
a linear correlation between the number of recombinants
that were obtained and the amount of oligonucleotide
transformed up to 100mg( R
2=0.98; Figure 2b). At
100mg of oligonucleotide we observed a 1000-fold
increase in recombineering efﬁciency over background
levels. No increase in recombinants could be obtained by
using >100mg of oligonucleotide as this signiﬁcantly
reduced cell viability and recombineering efﬁciency.
Co-transformation of carrier DNA or the use of oligo-
nucleotides with phosphorothiorate linkages to prevent
host nuclease activity did not increase the recombineering
efﬁciency in L. reuteri (data not shown).
Increased recombineering efﬁciency using mutations that
avoid mismatch repair
To assess if mismatch repair can be avoided in L. reuteri
in a similar way as described for E. coli (see introduction),
we designed an oligonucleotide (oJP311) with two
non-complementary bases, one of which yields a C C
mismatch that is, at least in E. coli, not efﬁciently
recognized by the MMR (Figure 2a). oJP311 also
showed a linear correlation (R
2=0.99) for the increase
in rifampicin-resistant colonies compared to the oligo-
nucleotide concentration that was transformed
(Figure 2b). The presence of an adjacent non-
complementary base that yields a C C mismatch did
increase the recombineering efﬁciency, yielding on
average 3±1-fold more recombinants when compared
to oJP133 (Figure 2b).
To assess whether the resultant C C mismatch com-
pletely avoids mismatch repair in L. reuteri we inactivated
two key players in MMR, mutS and mutL (see ‘Materials
and Methods’ section for details), followed by testing the
recombineering efﬁciencies with 100mg of the above oligo-
nucleotides. The MMR is only completely avoided when
an oligonucleotide yields a similar number of recombin-
ants in MutS
  and MutL
  strains compared to the
wild-type. The level of recombinants obtained with
oJP133 and oJP311 is on average 75-fold and 20-fold, re-
spectively, lower in the wild-type background compared to
MutS
  or MutL
  strains, demonstrating that in L. reuteri
mismatch repair is not completely avoided with a single
C C mismatch (Figure 2c). We also ﬁnd that, unlike in
E. coli, an oligonucleotide yielding multiple mismatches at
wobble positions (oJP813, Figure 2a) ﬂanking the
mutation yielding H488R in RpoB only partially
avoided mismatch repair (Figure 2c).
To investigate whether the MMR can be completely
avoided with an oligonucleotide with multiple adjacent
mismatches we designed an oligonucleotide (oJP577)
with ﬁve consecutive mismatches (Figure 2a). oJP577
yielded over a 100-fold increase in recombineering levels
compared to recombineering levels obtained with an
oligonucleotide with a single non-complementary base
yielding a C A mismatch. Next we assessed the
recombineering levels of oJP577 in the MMR-deﬁcient
strains, showing that ﬁve adjacent mismatches yields
similar levels of recombinants, showing that it completely
avoids the MMR in L. reuteri (Figure 2c). Notably this
level of recombineering yielded a 100000-fold increase in
recombineering compared to background levels, which
indicated we had sufﬁcient recombineering frequency to
generate mutations without the need for selection.
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Figure 2. Establishing and optimizing recombineering in L. reuteri.
(a) The dsDNA sequence of the targeted rpoB region of L. reuteri is
shown aligned with amino acids speciﬁed by each codon. On the left
the leading and lagging strand are indicated and below the oligonucleo-
tides are listed which result in different mismatches, all resulting in a
rifampicin-resistant phenotype. The corresponding amino acid changes
are listed on the right. (b) Titrations of the amount of oligonucleotides
oJP133 (O) and oJP577 () were performed with 1, 5, 25 and 100mgo f
oligonucleotide. Rifampicin resistant colonies derived from the control
transformation are represented as a bar graph. Data are expressed as
rifampicin-resistant cfu per 10
9 cells. Data shown are the averages of
three independent experiments and error bars represent standard devi-
ation. (c) Assessment of recombineering efﬁciencies with 100mg oJP133,
oJP311, oJP813 and oJP577 in the wild-type strain (black bars), and in
the mismatch repair deﬁcient strains MutS1
  (light grey bars) and
MutL
  (dark grey bars). Data shown are the averages of three inde-
pendent experiments and error bars represent standard deviation.
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L. reuteri
We use the term ‘non-selected recombineering’ for the
identiﬁcation of mutants within a pool of cells without
antibiotic or other phenotypic selection. Non-selected
targeted recombineering is a powerful time-efﬁcient
approach that allows, when avoiding the MMR, construc-
tion of strain variants that are comparable to strains
obtained through directed evolution. To identify if we
could perform non-selected recombineering in L. reuteri
we transformed oJP577, the most efﬁcient oligonucleotide
in this study, and plated the transformations on medium
without rifampicin selection. One hundred colonies were
picked from antibiotic-free plates and replica-plated on
plates containing rifampicin. We found 5% of the
transformants had incorporated the mutation into their
genome (Figure 3a). These results show that targeted
non-selected mutations can be made in L. reuteri.
To show that the non-selected recombineering is not
dependent on the location of rpoB, we targeted ten add-
itional genes in L. reuteri that are found at different loca-
tions in the chromosome (Figure 3b). For each of these
genes basepair changes were made without selection with
recombineering rates that ranged from 0.4% to 19%. This
demonstrates that non-selected recombineering can be
performed throughout the genome. Currently we are
investigating the basis for variation in recombineering ef-
ﬁciency at different loci.
Extending recombineering to other LAB
Current technologies do not allow the construction of
targeted point-mutations in a high-throughput manner
in L. lactis, a species with industrial and medical relevance
for its application in the dairy industry in fermentation
processes and its application as a biotherapeutic delivery
vehicle. As pJP042 is not functional in L. lactis MG1363
(data not shown), we switched to the well-established
nisin-inducible expression system for the expression of
RecT1 [for a review, see (50)]. We used L. lactis NZ9000
as the expression host for pJP005, a derivative of
pNZ8048 in which the L. reuteri recT1 gene was cloned
under the control of the nisin-inducible promoter PnisA.
We designed oligonucleotides with one and four
non-complementary bases that will yield a rifampicin re-
sistant phenotype (Figure 4a). In L. lactis recombineering
is more efﬁcient with an oligonucleotide (oJP563) with
multiple adjacent non-complementary bases as 50-fold
more recombinants were obtained compared to a single
non-complementary base that yields a T C mismatch
(Figure 4b). As observed in L. reuteri we ﬁnd in L. lactis
that recombineering efﬁciencies obtained with oJP563 are
high enough for non-selected recombineering, yielding a
1% efﬁciency (data not shown).
We also extended recombineering to two human isolates
of Lactobacillus whose genomes are publicly available:
L. plantarum BAA 793 (51) and L. gasseri ATCC 33323
(52). We used pJP042 in combination with 100mg oligo-
nucleotide that targets rpoB to yield the amino acid
changes D480Y and T489S+H490Y in L. plantarum
and L. gasseri, respectively. We show, without any
further optimization in these strains, that recombineering
in L. gasseri yields  10
4 rifampicin-resistant colonies with
an oligonucleotide containing ﬁve adjacent mismatches
(Figure 4c). We were only able to design an
oligonucleoitde with a single mismatch in L. plantarum
(oJP492) that yields a rifampicin-resistant phenotype,
yielding approximately 10
3 rifampicin-resistant colonies.
Although recombineering levels in both strains are lower
compared to L. reuteri and L. lactis, we anticipate that
optimization of electroporation conditions, testing RecT
from different hosts, optimizing expression levels of RecT,
combined with oligonucleotide design will further increase
the level of recombineering in these strains.
ssDNA recombineering did not yield untargeted genome
changes in L. reuteri and L. lactis
A major concern of recombineering, which so far has not
been adequately addressed in any organism, is the
MRS MRS + RIF
ori
rpoB  (5.0%) 
ddl (ND)
0130 (2.2%)
1706 (0.4%)
0214 (0.5%)
1161 (2.2%) 1097 (3.5%)
0808 (19.0%) 
0737 (12.2%) 
0919 (2.8%) 
1077 (1.1%)
1696 (0.4%)
(a)
(b)
Figure 3. Non-selected recombineering in L. reuteri.( a) One hundred
colonies derived from transformation with 100mg oJP577, which upon
incorporation yields a rifampicin-resistant phenotype (RpoB H488R),
were patched onto MRS agar without antibiotic selection (left—MRS),
and onto MRS agar containing rifampicin (right—MRS+RIF).
(b) Overview of a selection of genes mutated by non-selected
recombineering in the L. reuteri ATCC PTA 6475 chromosome. The
locations of the mutated genes on the L. reuteri ATCC PTA 6475
chromosome are indicated based on the closed genome of the closely
related strain L. reuteri F275 (NCBI accession number NC_010609).
The numbers displayed represent the last four digits of the locus tag
(HMPREF0535_XXXX) for each of the genes targeted and the
recombineering frequency shown in parentheses. The rpoB gene
(DNA directed RNA polymerase; locus tag HMPREF0536_0828) and
the ddl gene (D-Ala-D-Ala ligase, locus tag HMPREF0536_1572) are
listed using their gene names based on experimental evidence. ND:
not determined; ori: origin of replication.
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obtaining additional untargeted mutations and genome
rearrangements. In E. coli prolonged expression of the
 -Red genes yielded a hypermutagenic phenotype based
on the increase of natural rifampicin-resistant colonies
(53). To assess whether our approach is mutagenic we
sequenced the complete genome of three L. reuteri
strains: the wild-type control strain, a strain in which
RecT was expressed from pJP042 but not exposed to
ssDNA (RPRB0000), and a strain which has under-
gone a single recombineering event using 100mgo f
oligonucleotide o1696 that targets a putative
6-aminohexanoate-cyclic-dimer hydrolase (locus tag
HMPREF0536_1696; RPRB1696). In RPRB0000, a
single base insertion was identiﬁed in the gene encoding
dextransucrase (locus tag HMPREF0536_1850) resulting
in a frame-shift with a consequent stop codon down-
stream. In RPRB1696 we conﬁrmed the correct
mutation in locus tag HMPREF0536_1696 speciﬁed by
o1696. In addition we identiﬁed a single non-targeted
point-mutation in a gene encoding a putative transcription
regulation protein (locus tag HMPREF0536_1614), a G–
T transversion in the third base of the start codon.
We also sequenced the genome of a L. lactis strain that
has undergone a double recombineering event in which
rpoB (locus tag LLNZ_10235) and malG (locus tag
LLNZ_03840) were mutated (RPRB4004) simultaneously.
Compared to the control strain (RPRB4000) no point mu-
tations or other genome alterations were identiﬁed other
than the mutations introduced by the oligonucleotides.
Taken together these data indicate ssDNA
recombineering is speciﬁc and not hypermutagenic in the
sequenced L. reuteri and L. lactis isolates that have
undergone a recombineering event.
Using recombineering to create a vancomycin-sensitive
L. reuteri strain
To emphasize the utility of recombineering we converted
L. reuteri from vancomycin resistant to vancomycin sen-
sitive by mutating the active site of Ddl directly in the
chromosome. Vancomycin inhibits the peptidoglycan bio-
synthesis by binding to muramylpentapeptides that ter-
minate in D-alanyl-D-alanine (D-Ala-D-Ala) and blocks
the addition of these precursors into the peptidoglycan
backbone (54,55). Many lactobacilli incorporate D-
alanyl-D-lactate (D-Ala-D-Lac) into their muramylpen-
tapeptides, and this is the basis for their vancomycin
resistance as peptides that terminate in D-Ala-D-Lac are
bound 1000-fold less efﬁciently by vancomycin
compared to peptides terminating in D-Ala-D-Ala
(56,57). The enzyme responsible for the addition of D-
Ala or D-lac is D-Ala-D-Ala ligase (Ddl). In E. coli Ddl is
a dipeptide ligase as it catalyzes the formation of D-Ala-D-
Ala whereas in L. mesenteorides, and probably in many
lactobacilli, Ddl is a depsipeptide ligase as it catalyzes the
formation of D-Ala-D-Lac. Superimposing the structures
of Ddl-E. coli and Ddl-L. reuteri show that both proteins
are structurally related (Figure 5a). In vitro analyses in
E. coli and L. mesenteroides have previously identiﬁed
active site residues in Ddl that upon mutation could
switch from a dipeptide ligase to a depsipeptide ligase
and vice versa(34,58). In Ddl-E. coli the residues Y216–
E15–S150 form a hydrogen-bonding triad (Figure 5b) that
is linked with the speciﬁcity of the enzyme although the
exact mechanism for the shift in speciﬁcity is unknown
(34). By replacing the tyrosine at position 216 with a
phenylalanine (Y216F) in Ddl-E. coli there is no
hydrogen bond formed between F216–E15, and as a con-
sequence Ddl-Y216F has gained depsipeptide activity
(Figure 5b) (34). To translate this to L. reuteri,w e
identiﬁed the predicted active site residues in Ddl-
L. reuteri by superimposing Ddl-L. reuteri with Ddl-E.
coli (Fig 5c). The L. reuteri triad is predicted to be
F258–E17–S186, and mutating phenylalanine at position
258 to a tyrosine (F258Y) would, based on the E. coli
model, yield a hydrogen-bond between Y258-E17 and
change subsequently the enzyme activity from a
depsipeptide ligase to a dipeptide ligase. As a result the
cells render sensitivity to vancomycin.
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Figure 4. Establishing recombineering in other LAB. (a) The dsDNA
sequence of the targeted rpoB region of L. lactis is shown aligned with
the encoded amino acids for each codon. On the left are the leading
and lagging strand indicated and below oligonucleotides are listed
yielding different mismatches, all resulting in a rifampicin-resistant
phenotype. The corresponding amino acid changes are listed on the
right. (b) Recombineering efﬁciencies obtained in L. lactis transformed
with 100mg oJP547 or oJP563 and the level of natural rifampicin re-
sistant L. lactis colonies per 10
9 cells (control). (c) Comparison of
recombineering levels between L. reuteri (oJP577), L. lactis (oJP563),
L. gasseri (oJP579) and L. plantarum (oJP492). All data shown are
averages from three independent experiments and error bars represent
standard deviation.
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in the F258 codon of ddl along with bases in wobble pos-
itions in ﬂanking codons to generate the single amino acid
change F258Y (Figure 5d). The base changes disrupt an
ApoI restriction endonuclease site and therefore we
screened colonies by PCR ampliﬁcation of the target
region followed by ApoI restriction digest analysis. An
undigested amplicon was obtained (Supplementary
Figure S1) and we conﬁrmed by sequence analysis that
the mutation was successfully incorporated into the ddl
gene. The resulting strain RPRB3003 showed increased
sensitivity to vancomycin (MIC=1.5mg/ml) compared
L. reuteri wild type 
E. coli wild type 
E. coli Ddl-Y216F 
Y216:  
H-bond 
F216:   
no H-bond 
S150 
E15 
F258 E17 
S186 
Y216 
S150 
E15 
5’...GAA  AAC  AAA  TTT  GTG  GAT  GCC  AGT...3’ 
3’...CTT  TTG  TTT  AAA    CAC  CTA  CGG  TCA...5’
EN KFVDA
leading
lagging
TG oJP810 F258Y
S
C G T C A
(d)( e)
wild type RPRB3003
(a)( b)
(c)
Figure 5. Converting vancomycin-resistant L. reuteri to vancomycin-sensitive by a single amino acid change. (a) The determined 3D structure of the
D-ala-D-ala ligase (Ddl) protein of E.coli (PDB ID 1IOV; blue) and the modeled protein structure of Ddl of L. reuteri (green) were superimposed to
locate the putative active site residues in Ddl of L. reuteri which, in E. coli, form a hydrogen-bonded network (Y216–E15–S150; boxed region).
(b) Superimposing the determined structures of the Ddl proteins of the E. coli wild-type (blue) and a mutant (PDB ID 1IOW; grey) show that
replacing a tyrosine at position 216 with a phenylalanine (Y216F) does not form a hydrogen-bond between F216–E15, and changes the enzymatic
activity from a dipeptide ligase to a depsipeptide ligase. (c) We predicted the active site residues of Ddl-L. reuteri by superimposing the wild-type
E. coli Ddl protein (blue) with the predicted protein structure of L. reuteri (green), and residues F258–E17–S186 in Ddl-L. reuteri correspond to the
E. coli triad Y216–E15–S15, respectively. According to the E. coli model changing the phenylalanine at position 258 to a tyrosine (F258Y) in Ddl-L.
reuteri would establish a hydrogen-bond between F258–E17 and may therefore yield dipeptide ligase activity which subsequently would result in a
vancomycin-sensitive phenotype. (d) The dsDNA sequence of the ddl region of L. reuteri is shown aligned with the encoded amino acids for each
triplet. Italic sequence represents the ApoI restriction site that is mutated by incorporation of oJP810. On the left are the leading and lagging strand
indicated, and below is oJP810 showing the different mismatches with the resulting amino acid change (F258Y) on the right. (e) Susceptibility of
L. reuteri wild-type (left) and the mutant RPRB3003 (right) to vancomycin using an Etest assay. The MIC is determined by identifying where
bacterial growth intersects the Etest strip.
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onstrates that non-selected ssDNA recombineering may
be applied to strains used as biotherapeutic delivery
vehicles to remove undesirable characteristics, such as
unwanted antibiotic resistance.
DISCUSSION
We have adapted the ssDNA recombineering technology
to efﬁciently construct non-selected targeted mutations on
the chromosomes of L. reuteri and L. lactis and show
proof-of-concept in two other human-derived probiotic
lactobacilli. In optimizing this work we have uncovered
important parameters that should facilitate adaptation
of non-selected recombineering to other Firmicutes. Keys
to efﬁcient recombineering in LAB were (i) high ssDNA
concentration (up to 100mg), (ii) optimal electroporation
conditions and (iii) oligonucleotide design that will avoid
the MMR system. Efﬁcient recombineering required
100mg of oligonucleotide, nearly a 1000-fold excess over
the amount of oligonucleotide needed for optimal
recombineering in E. coli (14,49). We suspect the high
amount of oligonucleotide required is due to the inability
of ssDNA to enter the cells, presumably because of the
thick peptidoglycan layer found in Gram-positive
bacteria. Extensive degradation of ssDNA by host
nucleases, which can be overcome in E. coli by
co-transformation of carrier DNA or by using
phosphorothioate linkages in the oligonucleotide, is not
a major factor in L. reuteri. In contrast to E. coli, the
MMR in L. reuteri can only be avoided with an
oligonucleotide harbouring multiple consecutive non-
complementary bases. C C mismatches and multiple mu-
tations at wobble base positions can increase
recombineering efﬁciency, but are still 30-fold lower than
oligonucleotides containing ﬁve consecutive mismatches.
We do not understand why L. reuteri’s MMR system
appears to be more stringent than MMR of E. coli.
Finally, without optimization we achieved successful
ssDNA recombineering in the human-derived strains
L. plantarum and L. gasseri, and we envision that system-
atic optimization will further increase the efﬁciency of
recombineering. Currently the level of recombineering in
L. gasseri is high enough to isolate co-selected mutants in
a similar way as previously described in Mycobacterium
(15). We expect similar levels to be achieved in
L. plantarum with an oligonucleotide that avoids the
MMR.
When avoiding MMR, the efﬁciency of recombineering
in L. reuteri and L. lactis was high enough to obtain
non-selected mutants in a wild-type background. The gen-
eration of mutations in the chromosome without the need
for selection was previously only available in only E. coli
(14). Our demonstrated ability to subtly alter the genomes
of LAB by recombineering creates the possibility to
generate many molecular alterations that improve upon
existing technologies. These include the ability to
generate in-frame stop codons, to alter gene expression
via point mutations in promoters and ribosome-binding
sites, to enhance or change enzyme activity, and to
generate an unlimited number of mutations in a single
genome. Mutations can be generated in less than a
week, and in L. reuteri the plasmid DNA can easily be
cured from the cells as after a single passage without anti-
biotic selection 20% of the population have lost pJP042
(unpublished results, JPvP and RB). Our results
showed that ssDNA recombineering in both L. lactis
and L. reuteri isolates is speciﬁc, efﬁcient, and not
hypermutagenic. This opens up the possibility to apply
multiplex automated genome engineering (MAGE) (59)
and trackable multiplex recombineering (TRMR) (60),
elegant systems to perform genome-wide genetic
engineering.
There is increasing interest to apply lactococci and
lactobacilli as protein delivery vehicles for biotherapeutics
and vaccines. The majority of lactobacilli, however, have
intrinsic resistance to the antibiotic vancomycin (61,62). In
addition to the use of (lactobacilli) probiotics in healthy
individuals (63,64), it is anticipated that there will be
increased use of lactobacilli as delivery vehicles for thera-
peutics in patients with diseases and/or reduced immune
function. This raises serious safety concerns since
numerous cases which associate lactobacilli with bacter-
emia infections in immunocompromised patients have
been documented (65–69). Since vancomycin is the antibi-
otic most often used to treat Gram-positive bacteraemia
infections (70), engineered biotherapeutics that are sensi-
tive to clinically relevant levels of vancomycin would allow
efﬁcient eradication should a patient show signs of infec-
tion. To highlight the utility of ssDNA recombineering in
enhancing strain safety by enzyme modiﬁcation we altered
the enzymatic activity of the Ddl enzyme in L. reuteri.A
single amino acid change reduced the MIC to vancomycin
by two orders of magnitude to clinically relevant levels
(71). The mutation only caused a minor effect on growth
rate and growth yield (data not shown) and thus can be
further explored as a potential therapeutic delivery system.
Using recombineering it is now possible to generate a
strain that contains only a single-point mutation when
compared to the starting strain, without the need for se-
lection. This can be achieved by creating a 5-bp mutation
in a ﬁrst round of recombineering and then repairing four
of the mismatches back to the wild-type sequence in a
second round, resulting in a single nucleotide change.
Thus strains created by recombineering may contain a
single mutation that is molecularly indistinguishable
from mutations that arise via natural selection or
directed evolution. We therefore propose that strains
created by recombineering will be equally safe as strains
in which mutations are selected for in the laboratory and
we expect that RecT-mediated genetic engineering will
stimulate debate over the use of bacteria modiﬁed using
recombineering technology in industry and medicine.
SUPPLEMENTARY DATA
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